EG24483A - Rapid onset formulation - Google Patents

Rapid onset formulation

Info

Publication number: EG24483A
Authority: EG; Egypt
Prior art keywords: rapid onset; formulation; onset formulation; given; enterically
Prior art date: 2000-12-20

Application number

EG2002060693A

Other languages

English (en)

Inventor

Eric Gervais

Original Assignee

Duchesnay Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-20

Filing date

2002-06-19

Publication date

2009-08-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42104724&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24483(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-06-19 Application filed by Duchesnay Inc filed Critical Duchesnay Inc

2009-08-09 Application granted granted Critical

2009-08-09 Publication of EG24483A publication Critical patent/EG24483A/xx

Links

238000009472 formulation Methods 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 abstract 2
238000004090 dissolution Methods 0.000 abstract 2
230000003474 anti-emetic effect Effects 0.000 abstract 1
239000002111 antiemetic agent Substances 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
229960005008 doxylamine succinate Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
239000008363 phosphate buffer Substances 0.000 abstract 1
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 1
235000019171 pyridoxine hydrochloride Nutrition 0.000 abstract 1
239000011764 pyridoxine hydrochloride Substances 0.000 abstract 1
229940011671 vitamin b6 Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Seal Device For Vehicle (AREA)
Memory System Of A Hierarchy Structure (AREA)
Power Steering Mechanism (AREA)
Lubricants (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

EG2002060693A 2000-12-20 2002-06-19 Rapid onset formulation EG24483A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CA002350195A CA2350195C (fr)	2000-12-20	2000-12-20	Preparation a delai d'action rapide de chlorhydrate de pyridoxine et de doxylamine succinate
US09/885,051 US6340695B1 (en)	2000-12-20	2001-06-21	Rapid onset formulation
PCT/CA2001/000951 WO2003000263A1 (fr)	2000-12-20	2001-06-21	Forme galenique a court delai d'action

Publications (1)

Publication Number	Publication Date
EG24483A true EG24483A (en)	2009-08-09

Family

ID=42104724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EG2002060693A EG24483A (en)	2000-12-20	2002-06-19	Rapid onset formulation

Country Status (34)

Country	Link
US (1)	US6340695B1 (fr)
EP (1)	EP1397133B1 (fr)
JP (1)	JP4242763B2 (fr)
KR (1)	KR100527985B1 (fr)
CN (1)	CN1229112C (fr)
AT (1)	ATE307582T1 (fr)
AU (1)	AU2001272243B2 (fr)
BE (1)	BE1014929A4 (fr)
BR (1)	BR0107371A (fr)
CA (1)	CA2350195C (fr)
DE (2)	DE60114475T2 (fr)
DK (2)	DK1397133T3 (fr)
EG (1)	EG24483A (fr)
ES (1)	ES2251494T3 (fr)
FI (1)	FI117961B (fr)
FR (1)	FR2826277B1 (fr)
GB (1)	GB2383751C (fr)
GR (1)	GR1004371B (fr)
HU (1)	HU227003B1 (fr)
IL (1)	IL150349A0 (fr)
IS (1)	IS2225B (fr)
IT (1)	ITTO20020524A1 (fr)
LU (1)	LU90934B1 (fr)
MC (1)	MC200059A1 (fr)
MX (1)	MXPA02006037A (fr)
MY (1)	MY132786A (fr)
NL (1)	NL1020895C2 (fr)
NO (1)	NO332190B1 (fr)
PL (1)	PL204507B1 (fr)
SE (1)	SE526307C2 (fr)
TR (1)	TR200201685T1 (fr)
UA (1)	UA74807C2 (fr)
UY (1)	UY27352A1 (fr)
WO (1)	WO2003000263A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2350195C (fr) *	2000-12-20	2003-06-10	Duchesnay Inc.	Preparation a delai d'action rapide de chlorhydrate de pyridoxine et de doxylamine succinate
US8012506B2 (en) *	2001-04-10	2011-09-06	Pernix Therapeutics, Llc	Tannate compositions, methods of making and methods of use
US8257746B2 (en)	2001-04-10	2012-09-04	Pernix Therapeutics, Llc	Tannate compositions, methods of making and methods of use
ES2229876B1 (es) *	2001-06-26	2006-03-01	Duchesnay Inc.	Formulacion de accion rapida.
CA2392486A1 (fr) *	2002-07-05	2002-12-08	Duchesnay Inc.	Forme posologique pharmaceutique portant une inscription pour les femmes enceintes
CA2406592C (fr) *	2002-10-04	2003-09-30	Duchesnay Inc.	Mode de preparation de formes posologiques pharmaceutiques contenant de multiples principes actifs
JP2004231520A (ja) *	2003-01-28	2004-08-19	Nichiko Pharmaceutical Co Ltd	保存安定性及び溶出速度に優れた医薬組成物
US20050004181A1 (en) *	2003-07-03	2005-01-06	Duchesnay Inc.	Use of anti-emetic for pre and post operative care
CA103771S (en)	2003-07-22	2006-01-18	Duchesnay Inc	Pharmaceutical dosage form
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
US20060280789A1 (en) *	2004-12-27	2006-12-14	Eisai Research Institute	Sustained release formulations
US8481565B2 (en) *	2004-12-27	2013-07-09	Eisai R&D Management Co., Ltd.	Method for stabilizing anti-dementia drug
RU2445092C2 (ru) *	2005-04-28	2012-03-20	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Композиция, содержащая средство против деменции
US20070277530A1 (en) *	2006-05-31	2007-12-06	Constantin Alexandru Dinu	Inlet flow conditioner for gas turbine engine fuel nozzle
CN102108059B (zh) *	2010-09-03	2012-05-09	合肥工业大学	一种琥珀酸多西拉敏的合成方法
US8950188B2 (en)	2011-09-09	2015-02-10	General Electric Company	Turning guide for combustion fuel nozzle in gas turbine and method to turn fuel flow entering combustion chamber
NZ627593A (en) *	2012-02-22	2015-12-24	Duchesnay Inc	Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
WO2013123569A1 (fr) *	2012-02-22	2013-08-29	Duchesnay Inc.	Formulation à base de doxylamine et de pyridoxine et/ou de métabolites ou de sels associés
WO2013172297A1 (fr)	2012-05-14	2013-11-21	塩野義製薬株式会社	Préparation contenant un dérivé de 7-carbamoylmorphinane 6,7-insaturé
NZ716017A (en)	2013-07-22	2020-07-31	Duchesnay Inc	Composition for the management of nausea and vomiting
US9452181B2 (en)	2013-07-22	2016-09-27	Duchesnay Inc.	Composition for the management of nausea and vomiting
CN103432126A (zh) *	2013-08-05	2013-12-11	北京阜康仁生物制药科技有限公司	一种治疗孕吐的药物组合物
US9526703B2 (en)	2014-08-29	2016-12-27	Duchesnay Inc.	Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
SG11201701448XA (en) *	2014-08-29	2017-03-30	Duchesnay Inc	Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
CA2995431A1 (fr)	2015-08-17	2017-02-23	Aequus Pharmaceuticals Inc.	Administration transdermique de succinate de doxylamine et de chlorhydrate de piridoxine
CN105510512B (zh) *	2016-01-25	2018-06-29	南京济群医药科技股份有限公司	一种琥珀酸多西拉敏有关物质的rt-hplc检测方法
RS61368B1 (sr) *	2018-09-27	2021-02-26	Inibsa Ginecologia S A	Postupak za pripremu višejediničnog oralnog doznog oblika sa modifikovanim oslobađanjem doksilamin sukcinata i piridoksin hidrohlorida
CN114099450A (zh) *	2020-08-31	2022-03-01	长春海悦药业股份有限公司	一种比拉斯汀片及其制备方法
AU2021225255B1 (en) *	2021-09-03	2022-06-16	Patel, Mihir MR	Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting.
CN118638044A (zh) *	2023-03-13	2024-09-13	南京济群医药科技股份有限公司	一种快速释放的琥珀酸多西拉敏组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2085641A1 (en) *	1970-04-20	1971-12-31	Investigations Sci Pharm	Noramidopyrine doxylamine succinate compsn - antiinflammatories analgesics and antipyretics
US4642231A (en) *	1983-07-20	1987-02-10	Warner-Lambert Company	Magnesium trisilicate suitable for preparation of medicament adsorbates of antihistamines
DE69216642T2 (de) *	1992-01-13	1997-05-07	Pfizer	Verfahren zur herstellung von tabletten mit hoher festigkeit
CA2139896C (fr) *	1995-01-10	2000-03-28	Don B. Mcdonah	Utilisation d'un agent antinauseeux chez des patients en phase terminale
US6013280A (en) *	1997-10-07	2000-01-11	Fuisz Technologies Ltd.	Immediate release dosage forms containing microspheres
CN100391438C (zh) *	1999-09-14	2008-06-04	史密丝克莱恩比彻姆公司	制备水性包被小球粒的方法
CA2350195C (fr) *	2000-12-20	2003-06-10	Duchesnay Inc.	Preparation a delai d'action rapide de chlorhydrate de pyridoxine et de doxylamine succinate

2000
- 2000-12-20 CA CA002350195A patent/CA2350195C/fr not_active Expired - Lifetime
2001
- 2001-06-21 GB GB0213990A patent/GB2383751C/en not_active Expired - Lifetime
- 2001-06-21 MX MXPA02006037A patent/MXPA02006037A/es active IP Right Grant
- 2001-06-21 CN CNB018145485A patent/CN1229112C/zh not_active Expired - Fee Related
- 2001-06-21 DE DE60114475T patent/DE60114475T2/de not_active Expired - Lifetime
- 2001-06-21 DE DE10196426T patent/DE10196426T1/de not_active Ceased
- 2001-06-21 TR TR2002/01685T patent/TR200201685T1/xx unknown
- 2001-06-21 KR KR10-2002-7009679A patent/KR100527985B1/ko not_active Expired - Lifetime
- 2001-06-21 WO PCT/CA2001/000951 patent/WO2003000263A1/fr not_active Ceased
- 2001-06-21 JP JP2003506908A patent/JP4242763B2/ja not_active Expired - Fee Related
- 2001-06-21 HU HU0301950A patent/HU227003B1/hu unknown
- 2001-06-21 DK DK01951259T patent/DK1397133T3/da active
- 2001-06-21 EP EP01951259A patent/EP1397133B1/fr not_active Expired - Lifetime
- 2001-06-21 BR BR0107371-0A patent/BR0107371A/pt not_active Application Discontinuation
- 2001-06-21 ES ES01951259T patent/ES2251494T3/es not_active Expired - Lifetime
- 2001-06-21 UA UA2002065093A patent/UA74807C2/uk unknown
- 2001-06-21 IL IL15034901A patent/IL150349A0/xx active IP Right Grant
- 2001-06-21 US US09/885,051 patent/US6340695B1/en not_active Expired - Lifetime
- 2001-06-21 AU AU2001272243A patent/AU2001272243B2/en not_active Expired
- 2001-06-21 PL PL362763A patent/PL204507B1/pl unknown
- 2001-06-21 AT AT01951259T patent/ATE307582T1/de active
2002
- 2002-06-07 IS IS6412A patent/IS2225B/is unknown
- 2002-06-12 GR GR20020100280A patent/GR1004371B/el unknown
- 2002-06-18 NL NL1020895A patent/NL1020895C2/nl not_active IP Right Cessation
- 2002-06-18 IT IT2002TO000524A patent/ITTO20020524A1/it unknown
- 2002-06-19 EG EG2002060693A patent/EG24483A/xx active
- 2002-06-19 MY MYPI20022296A patent/MY132786A/en unknown
- 2002-06-20 BE BE2002/0397A patent/BE1014929A4/fr not_active IP Right Cessation
- 2002-06-20 DK DK200200947A patent/DK176018B1/da not_active IP Right Cessation
- 2002-06-20 NO NO20022982A patent/NO332190B1/no not_active IP Right Cessation
- 2002-06-20 FR FR0207643A patent/FR2826277B1/fr not_active Expired - Lifetime
- 2002-06-20 MC MC2486A patent/MC200059A1/fr unknown
- 2002-06-21 LU LU90934A patent/LU90934B1/fr active
- 2002-06-21 UY UY27352A patent/UY27352A1/es not_active Application Discontinuation
- 2002-07-03 SE SE0202061A patent/SE526307C2/sv unknown
- 2002-09-25 FI FI20021708A patent/FI117961B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
SE0202061L (sv)	2003-01-28
MY132786A (en)	2007-10-31
ES2251494T3 (es)	2006-05-01
DE60114475D1 (de)	2005-12-01
US6340695B1 (en)	2002-01-22
LU90934B1 (fr)	2002-12-23
EP1397133B1 (fr)	2005-10-26
FI20021708A0 (fi)	2002-09-25
KR20030023612A (ko)	2003-03-19
WO2003000263A1 (fr)	2003-01-03
FR2826277A1 (fr)	2002-12-27
GB0213990D0 (en)	2002-07-31
DK176018B1 (da)	2005-12-05
GB2383751B (en)	2005-02-09
HUP0301950A3 (en)	2005-06-28
MXPA02006037A (es)	2005-05-12
GB2383751A (en)	2003-07-09
FI117961B (fi)	2007-05-15
IS2225B (is)	2007-04-15
GR20020100280A (el)	2003-03-28
JP4242763B2 (ja)	2009-03-25
CN1447694A (zh)	2003-10-08
GB2383751C (en)	2008-08-05
NO20022982L (no)	2002-10-09
NO332190B1 (no)	2012-07-23
DE10196426T1 (de)	2003-08-21
KR100527985B1 (ko)	2005-11-09
IE20020488A1 (en)	2003-04-30
PL362763A1 (en)	2004-11-02
AU2001272243B2 (en)	2004-02-05
UA74807C2 (en)	2006-02-15
HK1052654A1 (en)	2003-09-26
CA2350195A1 (fr)	2001-08-11
SE526307C2 (sv)	2005-08-16
TR200201685T1 (tr)	2003-06-23
HUP0301950A2 (hu)	2003-11-28
UY27352A1 (es)	2002-09-30
DE60114475T2 (de)	2006-07-13
JP2004521146A (ja)	2004-07-15
DK200200947A (da)	2003-01-03
BR0107371A (pt)	2003-06-10
SE0202061D0 (sv)	2002-07-03
NO20022982D0 (no)	2002-06-20
DK1397133T3 (da)	2006-02-27
ITTO20020524A0 (it)	2002-06-18
NL1020895C2 (nl)	2003-03-13
FR2826277B1 (fr)	2004-07-02
MC200059A1 (fr)	2003-01-30
ATE307582T1 (de)	2005-11-15
IL150349A0 (en)	2003-12-23
ITTO20020524A1 (it)	2003-12-18
CA2350195C (fr)	2003-06-10
HU227003B1 (en)	2010-04-28
PL204507B1 (pl)	2010-01-29
FI20021708L (fi)	2002-12-22
EP1397133A1 (fr)	2004-03-17
IS6412A (is)	2002-12-22
BE1014929A4 (fr)	2004-06-01
CN1229112C (zh)	2005-11-30
GR1004371B (el)	2003-10-23
NL1020895A1 (nl)	2002-12-30

Publication	Publication Date	Title
EG24483A (en)	2009-08-09	Rapid onset formulation
PT2143420E (pt)	2014-09-30	Formulação contendo um ou mais mutantes da alfa-galactosidade a lisossomal para o tratamento da doença de fabry
IL206830A (en)	2013-06-27	Use of an integrin-containing antagonist of the alpha 1 subunit - of the integrin to prepare a drug for the treatment of osteoporosis
HUP0105302A2 (hu)	2002-07-29	2,3,4,5-Tetrahidro-1H-[1,4]benzodiazepin-3-hidroxámsavak mint mátrix metalloproteináz-inhibitorok, alkalmazásuk és eljárás az előállításukra
AU3301800A (en)	2000-10-16	1,4-diazabicyclo(3.2.2)nonane-4-carboxylate and carboxamide derivatives, production and use thereof in therapeutics
ZA200202521B (en)	2002-12-24	2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preprations containing said compounds.
WO2002004421A3 (fr)	2002-04-04	Analogues de pyridoxine et de pyridoxal utilises comme agents de therapie cardio-vasculaire
PL346764A1 (en)	2002-02-25	New oral formulation for 5-ht4
NO994822L (no)	1999-12-02	Immunotolerant protrombinkomplekspreparat
AU6539000A (en)	2001-03-13	Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue
EP1213017A3 (fr)	2003-11-12	Utilisation d'un agoniste du récepteur 5-HT2C pour traiter les bouffées de chaleur
BG105204A (en)	2001-11-30	Salts of paroxetine
AU2517199A (en)	1999-08-09	Method for producing a medicament which quickly dissolves in the mouth and whichcontains acarbose as an active agent
AU6237200A (en)	2001-02-13	A system, method and article of manufacture for operational maturity process assessment via capability level determination in a user administration process area
杨启 et al.	1999	Geometric Precision of Datum Line in Shell Plate Expansion Methods
谷湘潜 et al.	2001	A new method to improve the precision of time difference
Iftikhar	1994	" OH, THE LAND OF ZHONG HUA
Haight	2001	No slowdown in power-gen rental.
EP1321146A3 (fr)	2004-06-02	Inhibiteurs de la 17beta-hydroxysteroide deshydrogénase du type 5 et du type 3 ainsi que leurs méthodes d'utilisation
沈海铭 et al.	1997	Physiological Regulation of Calonyctinin Sweetpotato Development
ZA200102029B (en)	2002-07-12	Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microadenomas.